共 33 条
- [31] First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine (C), irinotecan (I) and oxaliplatin (O) (XELOXIRI): A pilot study by the gruppo oncologico Nord-Ovest (G. O. N. O.)ANNALS OF ONCOLOGY, 2007, 18 : 6 - 6Bursi, S.Masi, G.Loupakis, F.Antonuzzo, A.Tognarini, L.Sonaglio, C.Chiara, S.Pfanner, E.Brunetti, I.Petrini, I.Baldi, G. G.Barletta, M. T.Fornaro, L.Allegrini, G.Donati, S.Andreuccetti, M.Ricci, S.Falcone, A.
- [32] Randomized phase II study of panitumumab (Pmab) plus irinotecan (CPT-11) versus cetuximab (Cmab) + CPT-11 in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) after fluoropyrimidine (FU), CPT-11, and oxaliplatin (L-OHP) failure: WJOG6510GJOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)Sugimoto, NaotoshiSakai, DaisukeTamura, TakaoHara, HirokiNishina, TomohiroEsaki, TaitoOkuda, HiroyukiDenda, TadamichiTsuda, MasahiroSatoh, TarohMakiyama, AkitakaYamazaki, KentaroKuramochi, HidekazuHosokawa, AyumuTsuda, TakashiTaniguchi, HiroyaKishimoto, JunjiBoku, NarikazuHyodo, IchinosukeMuro, Kei
- [33] Randomized phase II study of panitumumab (Pmab) plus irinotecan (CPT-11) versus cetuximab (Cmab) plus CPT-11 in patients with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) following treatment with fluoropyrimidine, CPT-11, and oxaliplatin (L-OHP) chemotherapy: WJOG6510GJOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Sakai, DaisukeTaniguchi, HiroyaTamura, TakaoSugimoto, NaotoshiEsaki, TaitoOkuda, HiroyukiMatsumoto, ToshihikoYamazaki, KentaroDenda, TadamichiYamaguchi, KenseiTsuda, TakashiHosokawa, AyumuMakiyama, AkilakaToblmatsu, KazutoshiGoda, FuminoriOtsu, SatoshiKishimoto, JunilBoku, NarikazuNakamura, ShinichiroHyodo, Ichinosuke